oxaliplatin / Generic mfg.  >>  Phase 3
Welcome,         Profile    Billing    Logout  

102 Trials

   Remove FilterRemove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
oxaliplatin / Generic mfg.
SHR-A1811-309, CTR20234257: A randomized, open-label, active-controlled, multicenter phase III clinical study of SHR-A1811 for injection versus investigator-selected treatment regimen in patients with advanced colorectal cancer who have failed treatment with oxaliplatin, fluorouraci

Ongoing
3
120
China
trastuzumab rezetecan (SHR-A1811) - Jiangsu Hengrui Pharma, Lonsurf (trifluridine/tipiracil) - Servier, Otsuka, Stivarga (regorafenib) - Bayer, Fruzaqla (fruquintinib) - Takeda
Shanghai Hengrui Pharmaceutical Co., Ltd./ Jiangsu Hengrui Pharmaceutical Co., Ltd./ Suzhou Shengdia Biopharmaceutical Co., Ltd
Colorectal cancer
 
 
NCT00705029: Alpha-Lipoic Acid in Preventing Peripheral Neuropathy in Patients Receiving Chemotherapy for Cancer

Recruiting
3
244
US
alpha-lipoic acid, placebo
University of Medicine and Dentistry New Jersey, M.D. Anderson Cancer Center, Jarrow Formulas Inc
Neurotoxicity, Unspecified Adult Solid Tumor, Protocol Specific
01/09
 
2008-000837-23: mEOC: Chemotherapy in chemonaïve patients with mucinous ovarian cancer

Ongoing
3
336
Europe
Carboplatin, Paclitaxel, Oxaliplatin, Capecitabine, , Solution for infusion, Concentrate for solution for infusion, Tablet, Avastin
University College London, POLICLINICO UNIVERSITARIO AGOSTINO GEMELLI, , Roche
Mucinous ovarian cancer, stages II-IV and stage I recurrent, MUCINOUS OVARIAN CANCER CARCINOMA MUCINOSO OVAIO, Diseases [C] - Female diseases of the urinary and reproductive systems and pregancy complications [C13]
 
 
LOGiC, NCT00680901 / 2007-005725-29: - Lapatinib Optimization Study in ErbB2 (HER2) Positive Gastric Cancer: A Phase III Global, Blinded Study Designed to Evaluate Clinical Endpoints and Safety of Chemotherapy Plus Lapatinib

Checkmark ESMO 2013
Sep 2013 - Sep 2013: ESMO 2013
Checkmark ASCO-2013
Jun 2013 - Jun 2013: ASCO-2013
Checkmark For advanced HER2-positive gastric cancer
More
Active, not recruiting
3
545
Europe, Canada, US, RoW
Lapatinib, Tykerb, Tyverb, Placebo, Capecitabine, Oxaliplatin
Novartis Pharmaceuticals
Neoplasms, Gastrointestinal Tract
09/12
01/25
2016-004394-40: FOLFOXIRI plus Panitumumab or FOLFOX plus Panitumumab in the treatment of metastatic colorectal cancer. folfoxiri più panitumumab contro folfox più panitumumab nel carcinoma del colonretto metastatico.

Ongoing
3
432
Europe
Panitumumab, Fluorouracile, Oxaliplatino, Calcio Levofolinato, Irinotecan, [Panitumumab], [Fluorouracile], [Oxaliplatino], [Calcio Levofolinato], [Irinotecan], Solution for infusion, VECTIBIX - 20 MG/ML CONCENTRATO PER SOLUZIONE PER INFUSIONE - USO ENDOVENOSO 1 FLACONCINO (VETRO) 20 ML, FLUOROURACILE AHCL - 50MG/ML SOLUZIONE INIETTABILE O INFUSIONE 1 FLACONCINO IN VETRO DA 100 ML, OXALIPLATINO ACCORD - 5 MG/ML CONCENTRATO PER SOLUZIONE PER INFUSIONE 1 FLACONCINO IN VETRO DA 40 ML, CALCIO LEVOFOLINATO TEVA - 25 MG POLVERE PER SOLUZIONE INIETTABILE 1 FLACONCINO, IRINOTECAN CSC - 20 MG/ML CONCENTRATO PER SOLUZIONE PER INFUSIONE 1 FLACONCINO IN VETRO DA 15 ML
Fondazione GONO, Amgen, G.O.N.O.
Metastatic Colorectal Cancer Carcinoma Colorettale metastatico, colorectal cancer spread at distance tumore al colon retto diffuso a distanza, Diseases [C] - Cancer [C04]
 
 
2016-002272-27: Improvement of Outcome in Elderly Patients or Patients not eligible for high-dose chemotherapy with Aggressive Non-Hodgkin Lymphoma in first Relapse or Progression by adding Nivolumab to a standard chemotherapy.

Ongoing
3
388
Europe
Opdivo, Solution for injection, Opdivo
Saarland University, Bristol-Myers Squibb
Patients with first relapse or progression of aggressive Non-Hodgkin’s Lymphoma who are not eligible neither for autologous nor allogeneic stem cell transplantation, Patients with first relapse or progression of aggressive Non-Hodgkin’s Lymphoma who are not eligible neither for autologous nor allogeneic stem cell transplantation, Diseases [C] - Blood and lymphatic diseases [C15]
 
 
2018-000377-68: Treatment for Locally Advanced and/or Metastatic Adenocarcinoma of the Pancreas

Ongoing
3
218
Europe
Paclitaxel in cationic liposomes, EndoTAG-1, Powder and solvent for concentrate for solution for infusion
SynCore Biotechnology Co., Ltd., SynCore Biotechnology Co., Ltd.
Unresectable Locally Advanced/ Metastatic Adenocarcinoma of the Pancreas, Unresectable Locally Advanced/ Metastatic Adenocarcinoma of the Pancreas, Diseases [C] - Cancer [C04]
 
 
PRODIGY, NCT01515748: Docetaxel+Oxaliplatin+S-1 (DOS) Regimen as Neoadjuvant Chemotherapy in Advanced Gastric Cancer

Completed
3
530
RoW
Docetaxel (XRP6976), Oxaliplatin (SR96669), S-1 (1-(2-tetrahydrofuryl)-5-fluorouracil + 5-chloro-2, 4-dihydroxypyridine (CDHP) (Gimeracil) + Oxo (Oteracil)
Sanofi
Gastric Cancer
01/19
12/21
NCT03511963: A Clinical Study to Compare the Efficacy, Safety and Immunogenicity of HLX04 and Bevacizumab Combined XELOX or mFOLFOX6 in the First-line Treatment of mCRC

Active, not recruiting
3
677
RoW
HLX04 100 mg in 4 ml Injection, Avastin 100 mg in 4 ml Injection
Shanghai Henlius Biotech
Metastatic Colorectal Cancer (mCRC)
04/20
04/24
2020-000149-15: Combined chemotherapy and radiotherapy followed by planned surgery compared to combined chemotherapy and radiotherapy with surgery only when really needed, for patients with cancer in the esophagus.

Not yet recruiting
3
1020
Europe
Carboplatin, Paklitaxel, Cisplatin, 5-fluorouracil, Oxaliplatin, Calcium folinate, Concentrate for solution for infusion, Concentrate and solvent for solution for infusion, Solution for injection/infusion
Karolinska University Hospital, Karolinska University Hospital, Swedish Research Council
Resectable locally advanced squamous cell carcinoma (SCC) of the esophagus, Cancer in the gullet (esophagus), which is possible to operate., Diseases [C] - Cancer [C04]
 
 
CheckMate 649, NCT02872116 / 2016-001018-76: Efficacy Study of Nivolumab Plus Ipilimumab or Nivolumab Plus Chemotherapy Against Chemotherapy in Stomach Cancer or Stomach/Esophagus Junction Cancer

Checkmark Data from Checkmate-649 trial in advanced or metastatic gastric or gastroesophageal junction cancer at ASCO-GI 2023
Jan 2023 - Jan 2023: Data from Checkmate-649 trial in advanced or metastatic gastric or gastroesophageal junction cancer at ASCO-GI 2023
Checkmark From CheckMate-649 study in combination with chemo in the Chinese subgroup of adv/mets gastric cancer, gastroesophageal junction cancer, or esophageal adenocarcinoma
Apr 2021 - Apr 2021: From CheckMate-649 study in combination with chemo in the Chinese subgroup of adv/mets gastric cancer, gastroesophageal junction cancer, or esophageal adenocarcinoma
Checkmark Data from CheckMate 649 trial in combination with Yervoy for 1L gastric and esophageal cancers at ESMO 2020
More
Active, not recruiting
3
2031
Europe, Canada, Japan, US, RoW
Nivolumab, Opdivo, BMS-936558, Ipilimumab, Yervoy, BMS-734016, Oxaliplatin, Capecitabine, Leucovorin, Fluorouracil
Bristol-Myers Squibb, Ono Pharmaceutical Co. Ltd
Gastric Cancer, Gastroesophageal Junction Cancer, Esophageal Adenocarcinoma
05/20
05/24
2016-002393-12: Systemic oxaliplatin or in intra-arterial chemotherapy combined with LV5FU2 ± Irinotecan, and targeted therapy, in first-line treatment of metastatic colorectal cancer restricted to the liver Chimiothérapie par oxaliplatine en intra-veineux ou dans le foie combiné à une chimiothérapie par LV5FU2 ± Irinotécan, et une thérapie ciblée, en intraveineux chez des patients ayant un cancer colorectal métastatique limité au foie.

Not yet recruiting
3
348
Europe
Solution for infusion, ELOXATINE
Fédération Francophone de Cancérologie Digestive, AMGEN
colorectal cancer with hepatic metastasis Cancer colorectal métastatique au niveau hépatique, colon cancer and rectal cancer with liver metastasis cancer du côlon ou du rectum avec métastases au niveau du foie, Diseases [C] - Cancer [C04]
 
 
2020-000241-14: Study to Evaluate Loncastuximab Tesirine With Rituximab Versus Immunochemotherapy in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (LOTIS-5)

Ongoing
3
350
Europe, RoW
Loncastuximab Tesirine, Rituximab, Gemcitabine, Oxaliplatin, ADCT-402, Powder for concentrate for solution for infusion, Concentrate for solution for infusion, Powder for solution for infusion, TRUXIMA, Bendacitabin 38 mg/ml, Oxali-Bendalis 5 mg/ml
ADC Therapeutics SA, ADC THERAPEUTICS SA, ADC Therapeutics SA
Diffuse Large B-Cell Lymphoma (DLBCL), Lymphoma, Diseases [C] - Cancer [C04]
 
 
KEYNOTE-177, NCT02563002 / 2015-002024-89: Study of Pembrolizumab (MK-3475) vs Standard Therapy in Participants With Microsatellite Instability-High (MSI-H) or Mismatch Repair Deficient (dMMR) Stage IV Colorectal Carcinoma (MK-3475-177/)

Hourglass Jan 2021 - Dec 2021 : Overall survival data from KEYNOTE-177 trial for MSI-H 1L CRC
Checkmark From KEYNOTE-177 trial for DNA repair-deficient metastatic CRC at ESMO 2020
Sep 2020 - Sep 2020: From KEYNOTE-177 trial for DNA repair-deficient metastatic CRC at ESMO 2020
Checkmark Data from KEYNOTE-177 trial for metastatic colorectal cancer
May 2020 - May 2020: Data from KEYNOTE-177 trial for metastatic colorectal cancer
More
Completed
3
307
NA
mFOLFOX6, FOLFIRI, pembrolizumab, IV infusion, bevacizumab, cetuximab
Merck Sharp & Dohme LLC
Colorectal Carcinoma
02/21
07/23
STRATEGIC-1, NCT01910610 / 2013-001928-19: Multi-Line Therapy Trial in Unresectable Metastatic Colorectal Cancer

Active, not recruiting
3
464
Europe, RoW
FOLFIRI-cetuximab, mFOLFOX6-bevacizumab, OPTIMOX-bevacizumab, irinotecan-based chemo + bevacizumab, Anti-EGFR agent (cetuximab +/- irinotecan or panitumumab), XELOX + bevacizumab
GERCOR - Multidisciplinary Oncology Cooperative Group, Hoffmann-La Roche
Colorectal Cancer Metastatic
07/23
12/24
ORIENT-16, NCT03745170: Efficacy and Safety Evaluation of Sintilimab or Placebo in Combination With XELOX as First Line Treatment in Patients With Gastric Cancer

Checkmark Data from ORIENT-16 study in unresectable or metastatic gastric or gastroesophageal adenocarcinoma at ESMO 2021
Sep 2021 - Sep 2021: Data from ORIENT-16 study in unresectable or metastatic gastric or gastroesophageal adenocarcinoma at ESMO 2021
Completed
3
650
RoW
Sintilimab, IBI308, Oxaliplatin, Capecitabine, placebo
Innovent Biologics (Suzhou) Co. Ltd.
Gastric Cancer
06/21
10/22
2021-000317-17: Survival analysis after pre-surgical therapy in patients with resectable pancreatic cancer and risk factors ANÁLISIS DE SUPERVIVENCIA TRAS TRATAMIENTO ANTES DE LA CIRUGÍA EN CÁNCER DE PÁNCREAS RESECABLE CON FACTORES DE RIESGO

Ongoing
3
116
Europe
Irinotecan, Fluorouracil, Oxaliplatin, calcium folinate, Concentrate for solution for injection/infusion, Solution for infusion
Fundación para la Gestión de la Investigación Biomédica de Cádiz-INIBICA, Instituto de Salud Carlos III
Resectable pancreatic cancer and risk factors Cáncer de pancreas resecable con factores de riesgo, Non-operable pancreatic cancer plus other conditions that increase the possibility to adquire a disease Cancer de pancreas no operable mas otras condiciones que aumenten la posibilidad de adquirir una enfermedad, Diseases [C] - Cancer [C04]
 
 
2020-004906-79: A study to evaluate the efficacy of oxaliplatin- or gemcitabine-based chemotherapy after allocation by standard criteria or by genetic markers in patients with resected pancreatic carcinoma Studie zur Wirksamkeit einer Chemotherapie nach Operation beim Karzinom der Bauchspeicheldrüse, wobei die Zuteilung zur Oxaliplatin-basierten oder Gemcitabin-basierten Chemotherapie entweder nach klinischen Standardkriterien oder nach genetischen Markern erfolgt

Not yet recruiting
3
394
Europe
Gemcitabine, Capecitabine, 5-fluorouracil, Irinotecan, Calcium Folinate, Oxaliplatin, Powder for solution for infusion, Film-coated tablet, Solution for injection, Concentrate for solution for infusion, Solution for injection/infusion
Ruprecht-Karls-University Heidelberg, Medical Faculty represented by Universitätsklinikum Heidelberg, Dietmar Hopp Stiftung, Cancerforskningsfonden i Norrland
Resected pancreatic ductal adenocarcinoma operiertes duktales Pankreas-Adenokarzinom, Resected pancreatic ductal adenocarcinoma operiertes duktales Bauchspeicheldrüsen-Adenokarzinom, Diseases [C] - Cancer [C04]
 
 
NCT03813784: A Study to Evaluate SHR-1210 in Combination With Capecitabine + Oxaliplatin Sequenced by SHR-1210 + Apatinib as First-line Therapy in Treatment of Advanced Gastric Cancer

Active, not recruiting
3
887
RoW
SHR-1210, Capecitabine, Oxaliplatin, Apatinib
Jiangsu HengRui Medicine Co., Ltd.
Gastric Cancer, GastroEsophageal Cancer
02/22
03/23
RATIONALE 306, NCT03783442 / 2018-000587-28: A Study of Tislelizumab (BGB-A317) in Combination With Chemotherapy as First Line Treatment in Participants With Advanced Esophageal Squamous Cell Carcinoma

Checkmark Data from RATIONALE 306 trial for 1L locally advanced metastatic esophageal squamous cell carcinoma at ASCO-GI 2023
Dec 2022 - Dec 2022: Data from RATIONALE 306 trial for 1L locally advanced metastatic esophageal squamous cell carcinoma at ASCO-GI 2023
Checkmark Presentation of data from RATIONALE 306 trial for 1L locally advanced metastatic ESCC at ESMO GI 2022
Jun 2022 - Jun 2022: Presentation of data from RATIONALE 306 trial for 1L locally advanced metastatic ESCC at ESMO GI 2022
Checkmark Data from RATIONALE 309 trial for 1L locally advanced, recurrent or metastatic ESCC
More
Active, not recruiting
3
649
Europe, Japan, US, RoW
Cisplatin, Oxaliplatin, Fluorouracil (5-FU), Capecitabine, Paclitaxel, Tislelizumab, BGB-A317, Placebo
BeiGene
Esophageal Squamous Cell Carcinoma (ESCC)
02/22
08/24
NCT04809142: A Study of TQB2450 Injection Combined With Anlotinib Hydrochloride Capsule as Second-line Treatment in Subjects With Advanced Biliary Cancer

Recruiting
3
392
RoW
TQB2450 Injection, Anlotinib hydrochloride, Oxaliplatin injection, Capecitabine tablets, Gemcitabine hydrochloride injection
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Advanced Biliary Cancer
03/22
02/23
CAIRO4, NCT01606098: The Role of Surgery of the Primary Tumour in Patients With Synchronous Unresectable Metastases of Colorectal Cancer

Completed
3
206
Europe
Surgery of the primary tumour, Systemic treatment, Bevacizumab in combination with fluoropyrimidine-based schedules
Dutch Colorectal Cancer Group, Hoffmann-La Roche
Colon Cancer, Primary Tumour, Rectal Cancer
06/22
12/22
YWPPEOPNCT, NCT04690283: Yiqi Wenjing Prescriptions Preventive Efficacy of Oxaliplatin-induced Peripheral Neuropathy Clinical Trial

Not yet recruiting
3
360
NA
Mimetic granules of Yiqi-Wenjing prescriptions, Mimetic granules of Huangqi-Guizhi-Wuwu plus Danggui-Sini decoction, Huangqi-Guizhi-Wuwu granules, Danggui-Sini granules
Nanjing NingQi Medicine Science and Technology Co., Ltd., Jiangsu Provincial Hospital of Integrated Traditional Chinese and Western Medicine, The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School, The First Affiliated Hospital with Nanjing Medical University, Jiangsu Cancer Institute & Hospital, Fudan University
Chemotherapy-induced Peripheral Neuropathy, Colorectal Cancer
07/22
10/22
UNION, NCT04928807: Short-Course Radiotherapy Followed by Neoadjuvant Chemotherapy and Camrelizumab in Locally Advanced Rectal Cancer

Active, not recruiting
3
231
RoW
Short course radiotherapy sequential camrelizumab and chemotherapy
Wuhan Union Hospital, China, Jiangsu HengRui Medicine Co., Ltd.
Rectal Cancer
03/23
03/26
Spotlight, NCT03504397 / 2017-002567-17: A Phase 3 Efficacy, Safety and Tolerability Study of Zolbetuximab (Experimental Drug) Plus mFOLFOX6 Chemotherapy Compared to Placebo Plus mFOLFOX6 as Treatment for Gastric and Gastroesophageal Junction (GEJ) Cancer

Checkmark Data from SPOTLIGHT trial in combination with mFOLFOX6 chemotherapy for gastric/gastroesophageal junction cancer
Dec 2022 - Dec 2022: Data from SPOTLIGHT trial in combination with mFOLFOX6 chemotherapy for gastric/gastroesophageal junction cancer
Active, not recruiting
3
566
Europe, Canada, Japan, US, RoW
zolbetuximab, IMAB362, placebo, oxaliplatin, folinic acid, fluorouracil
Astellas Pharma Global Development, Inc.
Locally Advanced Unresectable Gastroesophageal Junction (GEJ) Adenocarcinoma or Cancer, Locally Advanced Unresectable Gastric Adenocarcinoma or Cancer, Metastatic Gastric Adenocarcinoma or Cancer, Metastatic Gastroesophageal Junction (GEJ) Adenocarcinoma
09/22
03/25
KEYNOTE-859, NCT03675737 / 2018-001757-27: Pembrolizumab (MK-3475) Plus Chemotherapy Versus Placebo Plus Chemotherapy in Participants Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma (MK-3475-859/)

Checkmark Topline data from KEYNOTE-859 trial for HER2- 1L advanced gastric or gastroesophageal junction adenocarcinoma
Nov 2022 - Nov 2022: Topline data from KEYNOTE-859 trial for HER2- 1L advanced gastric or gastroesophageal junction adenocarcinoma
Active, not recruiting
3
1579
Europe, Canada, Japan, US, RoW
Pembrolizumab, KEYTRUDA®, MK-3475, Cisplatin, PLATINOL®, 5-fluorouracil, ADRUCIL®, 5FU, oxaliplatin, ELOXATIN®, capecitabine, XELODA®, Placebo for Pembrolizumab
Merck Sharp & Dohme LLC
Stomach Neoplasms
10/22
03/25
GLOW, NCT03653507 / 2018-000519-26: A Study of Zolbetuximab (IMAB362) Plus CAPOX Compared With Placebo Plus CAPOX as First-line Treatment of Subjects With Claudin (CLDN) 18.2-Positive, HER2-Negative, Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma

Checkmark Top-line data from GLOW trial in combination with CAPOX for gastric/gastroesophageal junction adenocarcinoma
Dec 2022 - Dec 2022: Top-line data from GLOW trial in combination with CAPOX for gastric/gastroesophageal junction adenocarcinoma
Active, not recruiting
3
507
Europe, Canada, Japan, US, RoW
zolbetuximab, IMAB362, oxaliplatin, capecitabine, placebo
Astellas Pharma Global Development, Inc.
Locally Advanced Unresectable Gastroesophageal Junction (GEJ) Adenocarcinoma or Cancer, Locally Advanced Unresectable Gastric Adenocarcinoma or Cancer, Metastatic Gastric Adenocarcinoma or Cancer, Metastatic Gastroesophageal Junction (GEJ) Adenocarcinoma
10/22
03/25
AGENT, NCT03750786 / 2017-004154-41: A Study to Compare the Efficacy of Arfolitixorin Versus Leucovorin in Combination With 5 Fluorouracil, Oxaliplatin, and Bevacizumab in Patients With Advanced Colorectal Cancer

Completed
3
490
Europe, Canada, Japan, US, RoW
Arfolitixorin, Leucovorin
Isofol Medical AB
Colo-rectal Cancer
11/22
11/22
GAPSO, NCT03801668: Albumin-bound Paclitaxel Plus S-1 Versus SOX as First-line Treatment in Advanced or Recurrent Gastric Adenocarcinoma

Recruiting
3
294
RoW
Albumin-bound Paclitaxel plus S-1, Oxaliplatin plus S-1
Huazhong University of Science and Technology, CSPC Ouyi Pharmaceutical Co., Ltd.
Gastric Cancer
12/22
03/23
ZUMA-7, NCT03391466 / 2017-002261-22: Study of Effectiveness of Axicabtagene Ciloleucel Compared to Standard of Care Therapy in Patients With Relapsed/Refractory Diffuse Large B Cell Lymphoma

Checkmark Data from ZUMA-7 trial (Abstract #659) in 2L DLBCL at ASH 2022
Dec 2022 - Dec 2022: Data from ZUMA-7 trial (Abstract #659) in 2L DLBCL at ASH 2022
Checkmark Data from ZUMA-7 trial (Abstract #259) in 2L DLBCL at ASH 2022
Dec 2022 - Dec 2022: Data from ZUMA-7 trial (Abstract #259) in 2L DLBCL at ASH 2022
Checkmark Data from ZUMA-7 trial for 2L DLBCL at ASCO 2022
More
Active, not recruiting
3
359
Europe, Canada, US, RoW
Axicabtagene Ciloleucel, KTE-C19, axi-cel, Yescarta ®, Platinum-containing salvage chemotherapy (eg, R-ICE) followed by high dose therapy (eg, BEAM) and autologous stem cell transplant in responders., Cyclophosphamide, Fludarabine
Kite, A Gilead Company
Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL)
03/21
10/24
NCT04675983: A Study of Sintilimab Plus Ramucirumab as First-line Treatment for G/EGJ Adenocarcinoma (ORIENT-106)

Terminated
3
36
RoW
Sintilimab, Tyvyt, IBI308, Ramucirumab, LY3009806, IMC-1121B, Cyramza, Cisplatin, 5-fluorouracil, Oxaliplatin, Capecitabine
Innovent Biologics (Suzhou) Co. Ltd.
Gastric Adenocarcinoma
02/23
02/23
PRESERVE 1, NCT04607668 / 2019-003826-25: Trilaciclib, a CDK 4/6 Inhibitor, in Patients Receiving FOLFOXIRI/Bevacizumab for Metastatic Colorectal Cancer (mCRC):

Jan 2023 - Jun 2023: From PRESERVE1 trial for metastatic colorectal cancer
Checkmark Approved Clinical Trial Application in China for metastatic CRC
Apr 2021 - Apr 2021: Approved Clinical Trial Application in China for metastatic CRC
Terminated
3
326
Europe, US, RoW
Trilaciclib, G1T28, CDK 4/6 inhibitor, Placebo
G1 Therapeutics, Inc.
Colorectal Cancer Metastatic, Myelosuppression-Adult, Chemotherapeutic Toxicity
02/23
03/23
RATIONALE 305, NCT03777657 / 2018-000312-24: Tislelizumab in Combination With Chemotherapy as First-Line Treatment in Adults With Inoperable, Locally Advanced or Metastatic Gastric, or Gastroesophageal Junction Carcinoma

Hourglass Jan 2023 - Dec 2023 : Submission in US for 1L gastric cancer
Checkmark Data from RATIONALE 305 trial in combination with chemotherapy 1L treatment for G/GEJ adenocarcinoma at ASCO-GI 2023
Jan 2023 - Jan 2023: Data from RATIONALE 305 trial in combination with chemotherapy 1L treatment for G/GEJ adenocarcinoma at ASCO-GI 2023
Checkmark Data from RATIONALE 305 trial in combination with chemotherapy 1L treatment for G/GEJ adenocarcinoma
Jan 2022 - Jan 2022: Data from RATIONALE 305 trial in combination with chemotherapy 1L treatment for G/GEJ adenocarcinoma
Active, not recruiting
3
997
Europe, Japan, US, RoW
Tislelizumab, BGB-A317, Placebo, Cisplatin, Oxaliplatin, Capecitabine, 5-FU
BeiGene
Gastric, or Gastroesophageal Junction Adenocarcinoma
02/23
12/24
ATTRACTION-5, NCT03006705: Study of Adjuvant ONO-4538 With Resected Gastric Cancer

Checkmark From ATTRACTION-5 trial for adjuvant gastric cancer and esophagogastric junction cancer
Dec 2022 - Dec 2022: From ATTRACTION-5 trial for adjuvant gastric cancer and esophagogastric junction cancer
Completed
3
800
Japan, RoW
Nivolumab, BMS-936558, ONO-4538, MDX-1106, Tegafur-gimeracil-oteracil potassium, Oxaliplatin, Capecitabine, Placebo
Ono Pharmaceutical Co. Ltd, Bristol-Myers Squibb
Gastric Cancer
08/22
03/23
2022-002214-17: Repeat local treatment +/- neoadjuvant systemic therapy for recurrent colorectal liver metastases. Lokale behandeling +/- neoadjuvant systemische therapie voor recidieven van leveruitzaaiingen van dikke- en endeldarmkanker.

Ongoing
3
360
Europe
CAPOX (capecitabine with oxaliplatin) FOLFOX/FOLFIRI (5-fluorouracil/leucovorin with oxaliplatin or, Concentrate for solution for infusion, CAPOX (capecitabine with oxaliplatin) FOLFOX/FOLFIRI (5-fluorouracil/leucovorin with oxaliplatin or irinotecan) (with or without bevacizumab, per-patient based)
Amsterdam University Medical Centers, Amsterdam University Medical Centers
Recurrent colorectal liver metastases Recidief colorectale levermetastasen, Recurrent liver metastases from colorectal cancer Recidief lever uitzaaiingen van dikke- en endeldarmkanker, Diseases [C] - Cancer [C04]
 
 
GEMSTONE-303, NCT03802591: A Study of CS1001 in Subjects With Gastric Adenocarcinoma or Gastro-Esophageal Junction Adenocarcinoma

Hourglass Jan 2023 - Jun 2023 : NDA filing in mainland China in 1L metastatic gastric adenocarcinoma/gastro-esophageal cancer
Hourglass Oct 2022 - Mar 2023 : Topline readout of the P3 trial in 1L metastatic gastric adenocarcinoma/gastro-esophageal junction adenocarcinoma
Completed
3
479
RoW
CS1001 monoclonal antibody, CS1001 placebo, Oxaliplatin, Capecitabine
CStone Pharmaceuticals
Gastric Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma
07/23
09/23
NCT04342936: Study of Camrelizumab (SHR-1210) vs. Chemotherapy in Participants With Relapsed or Refractory Classical Hodgkin Lymphoma

Recruiting
3
56
RoW
Camrelizumab, SHR-1210, Investigator's choice of Chemotherapy
Jiangsu HengRui Medicine Co., Ltd.
Classical Hodgkin Lymphoma
08/23
12/23
NCT05378867: A Study Assessing the Interchangeability Between TRS003 and Bevacizumab® For CRC

Not yet recruiting
3
126
NA
TRS003, China-approved Bevacizumab, mFOLFOX6
Zhejiang Teruisi Pharmaceutical Inc.
Metastatic Colorectal Cancer (CRC)
10/23
07/24
KEYNOTE 811, NCT03615326 / 2018-000224-34: Pembrolizumab/Placebo Plus Trastuzumab Plus Chemotherapy in Human Epidermal Growth Factor Receptor 2 Positive (HER2+) Advanced Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma (MK-3475-811/KEYNOTE-811)

Checkmark From KEYNOTE-811 for patients with HER2+ advanced gastric or gastroesophageal junction adenocarcinoma at ASCO 2021
Jun 2021 - Jun 2021: From KEYNOTE-811 for patients with HER2+ advanced gastric or gastroesophageal junction adenocarcinoma at ASCO 2021
Active, not recruiting
3
738
Europe, Japan, US, RoW
Pembrolizumab, Keytruda®, MK-3475, Placebo, Cisplatin, 5-FU, Oxaliplatin, Capecitabine, S-1, Trastuzumab, Herceptin®
Merck Sharp & Dohme LLC
Gastric Neoplasms, Gastroesophageal Junction Adenocarcinoma
03/24
12/24
NCT06177041: M108 Plus CAPOX Versus Placebo Plus CAPOX as First-line Treatment for Claudin (CLDN) 18.2-Positive, HER2-Negative, PD-L1 CPS<5, Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma.

Recruiting
3
486
RoW
M108 monoclonal antibody, Placebo, Oxaliplatin, Capecitabine
FutureGen Biopharmaceutical (Beijing) Co., Ltd
Locally Advanced Unresectable or Metastatic Gastric Cancer, Locally Advanced Unresectable or Metastatic Gastroesophageal Junction (GEJ) Adenocarcinoma
01/27
04/27
LAPIS, NCT03941093 / 2019-001925-28: Evaluation of Efficacy and Safety of Neoadjuvant Treatment With Pamrevlumab in Combination With Chemotherapy (Either Gemcitabine Plus Nab-paclitaxel or FOLFIRINOX) in Participants With Locally Advanced Pancreatic Cancer

Active, not recruiting
3
284
Europe, Canada, US, RoW
Pamrevlumab + Gemcitabine + Nab-paclitaxel or Pamrevlumab + FOLFIRINOX, FG-3019, Gemzar, Abraxane, Eloxitan, Leucovorin, Camptosar, 5-Fluracil, Efudex, Placebo + Gemcitabine + Nab-paclitaxel or Placebo + FOLFIRINOX
FibroGen
Pancreatic Cancer Non-resectable
04/24
04/24
COMPASSIOn-15, NCT05008783: A Study of AK104 in the First-line Treatment of Locally Advanced Unresectable or Metastatic G/GEJ Adenocarcinoma

Active, not recruiting
3
610
RoW
AK104, Oxaliplatin, Capecitabine, Placebo
Akeso
Gastric Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma
08/24
04/25
CRC01, NCT06226857: Other Oncogene Mutations for Anti-EGFR Efficacy in Patients With Left-sided RAS-wild Type Metastatic Colorectal Cancer

Recruiting
3
355
RoW
Cetuximab, panitumumab
City Clinical Oncology Hospital No 1, Atlas Biomed, N.N. Blokhin National Medical Research Center of Oncology, Moscow MultidisciplinaryClinical Center Kommunarka
Colorectal Neoplasms, Chemotherapy Effect, Molecular Sequence Variation
12/26
12/27
NCT06206733: ASKB589 in Combination With CAPOX and PD-1 Inhibitor in Patients With Advanced or Metastatic GC/GEJ Adenocarcinoma

Recruiting
3
780
RoW
ASKB589, Oxaliplatin, Capecitabine, Tislelizumab, Placebo
AskGene Pharma, Inc., Jiangsu Aosaikang Pharmaceutical Co., Ltd.
Gastroesophageal Junction Adenocarcinoma, Gastric Adenocarcinoma
12/26
12/28
KN035-BTC, NCT03478488: Programmed Death Ligand (PD-L1) Combined With Chemotherapy for Patients With BTC

Recruiting
3
480
RoW
KN035 plus Gemcitabine & oxaliplatin, Experimental, Gemcitabine & oxaliplatin, Active Comparator
3D Medicines (Sichuan) Co., Ltd.
Biliary Tract Neoplasms
07/24
07/24
KEYNOTE-585, NCT03221426 / 2016-004408-76: Study of Pembrolizumab (MK-3475) Plus Chemotherapy Versus Placebo Plus Chemotherapy in Participants With Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma (MK-3475-585/)

Calendar Jan 2024 - Dec 2024: From P3 KEYNOTE-585 trial for patients with gastric and gastroesophageal junction adenocarcinoma
Active, not recruiting
3
1007
Europe, Canada, Japan, US, RoW
Pembrolizumab, MK-3475, KEYTRUDA®, Placebo, Normal saline solution, Cisplatin, PLATINOL®, Capecitabine, XELODA®, 5-fluorouracil, ADRUCIL®, 5FU, Docetaxel, TAXOTERE®, Oxaliplatin, ELOXATIN®, Leucovorin, WELLCOVORIN®
Merck Sharp & Dohme LLC
Gastric Cancer, Gastroesophageal Junction Cancer
02/24
06/25
KEYNOTE-585 China Extension study, NCT04882241: Study of Pembrolizumab (MK-3475) Plus Chemotherapy Versus Placebo Plus Chemotherapy in Participants With Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma (MK-3475-585/KEYNOTE-585)-China Extension

Active, not recruiting
3
115
RoW
Pembrolizumab, MK-3475, KEYTRUDA®, Placebo, Normal saline solution, Cisplatin, PLATINOL®, Capecitabine, XELODA®, 5-fluorouracil, ADRUCIL®, 5FU, Docetaxel, TAXOTERE®, Oxaliplatin, ELOXATIN®, Leucovorin, WELLCOVORIN®
Merck Sharp & Dohme LLC
Gastric Cancer, Gastroesophageal Junction Cancer
02/24
06/25
SHR-A1811-309, NCT06199973: Injection of SHR-A1811 Versus Physician Choiced Treatment in Patients With Advanced Colorectal Cancer Who Had Failed to Respond to Oxaliplatin, 5-fu, and Irinotecan

Recruiting
3
120
RoW
SHR-A1811, TAS-102, Regorafenib , Fruquintinib
Suzhou Suncadia Biopharmaceuticals Co., Ltd.
Advanced Colorectal Cancer
04/26
06/26
NCT03362177 / 2017-002992-25: Study of Romiplostim for Chemotherapy-induced Thrombocytopenia in Adult Subjects With Gastrointestinal, Pancreatic, or Colorectal Cancer

Active, not recruiting
3
162
Europe, Canada, US, RoW
Romiplostim, Placebo
Amgen
Chemotherapy-induced Thrombocytopenia
01/24
01/25
PARADIGM biomarker, NCT02394834: An Exploratory Study of Treatment Sensitivity and Prognostic Factors in a Efficacy and Safety Study of mFOLFOX6 + Bevacizumab Versus mFOLFOX6 + Panitumumab Therapy in Patients With Chemotherapy-naïve Unresectable Advanced or Recurrent Colorectal Cancer

Active, not recruiting
3
757
Japan
oxaliplatin (OXA), levofolinate calcium (l-LV), 5-FU, panitumumab, oxaliplatin (OXA), levofolinate calcium (l-LV), 5-FU, bevacizumab
Takeda
Colorectal Cancer
03/25
03/25
KRYSTAL-10, NCT04793958 / 2020-004048-27: Phase 3 Study of MRTX849 With Cetuximab vs Chemotherapy in Patients With Advanced Colorectal Cancer With KRAS G12C Mutation

Active, not recruiting
3
461
Europe, Canada, US, RoW
MRTX849, Cetuximab, Erbitux, mFOLFOX6 Regimen, FOLFIRI Regimen
Mirati Therapeutics Inc.
Advanced Colorectal Cancer, Metastatic Colorectal Cancer
02/25
02/26
CIME, NCT06346197: Combination of Immune Checkpoint in Locally Advanced or Metastatic MSI/dMMR Esogastric Adenocarcinomas

Not yet recruiting
3
124
Europe
Balstilimab, Botensilimab, Folfox Protocol, XELOX, Nivolumab
Centre Leon Berard, Agenus Inc.
Gastric Cancer, MSI-H, Metastatic Cancer, Advanced Cancer
05/28
05/28
HERIZON-GEA-01, NCT05152147 / 2021-000296-36: A Study of Zanidatamab in Combination With Chemotherapy Plus or Minus Tislelizumab in Patients With HER2-positive Advanced or Metastatic Gastric and Esophageal Cancers

Recruiting
3
918
Europe, Canada, Japan, RoW
Zanidatamab, ZW25, JZP598, Tislelizumab, Trastuzumab, Herceptin®, Capecitabine, Oxaliplatin, Cisplatin, 5-Fluorouracil
Jazz Pharmaceuticals, BeiGene, Ltd.
Gastric Neoplasms, Gastroesophageal Adenocarcinoma, Esophageal Adenocarcinoma
12/24
07/25
CR-SEQUENCE, NCT03635021 / 2018-000347-60: Study to Evaluate the Efficacy of FOLFOX + Panitumumab Followed by FOLFIRI + Bevacizumab (Sequence 1) Versus FOLFOX + Bevacizumab Followed by FOLFIRI + Panitumumab (Sequence 2) in Untreated Patients With Wild-type RAS Metastatic, Primary Left-sided, Unresectable Colorectal Cancer

Active, not recruiting
3
419
Europe
FOLFOX regimen, Panitumumab, Bevacizumab, FOLFIRI regimen
Spanish Cooperative Group for the Treatment of Digestive Tumours (TTD), Amgen
Colorectal Cancer
06/25
06/25
COMPOSE, NCT04919226 / 2021-001086-20: Lutetium 177Lu-Edotreotide Versus Best Standard of Care in Well-differentiated Aggressive Grade-2 and Grade-3 GastroEnteroPancreatic NeuroEndocrine Tumors (GEP-NETs) -

Recruiting
3
202
Europe, US, RoW
177Lu-Edotreotide (Peptide Receptor Radionuclide Therapy) PRRT, 177Lu-DOTATOC 177Lu-Edo, CAPTEM (Capecitabine and Temozolomide), Amino-Acid Solution, Arginine-Lysine Solution, Everolimus, FOLFOX (Folinic acid + Fluorouracil + Oxaliplatin)
ITM Solucin GmbH
Neuroendocrine Tumors
06/27
09/27
POLARGO, NCT04182204 / 2018-003727-10: A Study to Evaluate the Safety and Efficacy of Polatuzumab Vedotin in Combination With Rituximab, Gemcitabine and Oxaliplatin Compared to Rituximab, Gemcitabine and Oxaliplatin Alone in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma

Active, not recruiting
3
270
Europe, Canada, US, RoW
Polatuzumab Vedotin, Rituximab, Mabthera; Rituxan, Gemcitabine, Oxaliplatin
Hoffmann-La Roche
Diffuse Large B-Cell Lymphoma
09/24
03/25
NCT04135781: Nab-paclitaxel Combined With S-1 as Adjuvant Chemotherapy for Stage Ⅲ Gastric Cancer

Recruiting
3
616
RoW
nab paclitaxel, albumin bound paclitaxel, Tegafur, S-1, Oxaliplatin, Capecitabine
Zhejiang Cancer Hospital, CSPC Ouyi Pharmaceutical Co., Ltd.
Stomach Cancer
10/24
10/24
TRIPLET-III, NCT05313282: A Trial of Hepatic Arterial Infusion Combined With Apatinib and Camrelizumab Versus Apatinib and Camrelizumab for C-staged Hepatocellular Carcinoma in BCLC Classification

Recruiting
3
140
RoW
Hepatic Arterial Infusion combined with Apatinib and Camrelizumab, Apatinib combined with Camrelizumab
Sun Yat-sen University, Jiangsu HengRui Medicine Co., Ltd.
C-staged Hepatocellular Carcinoma in BCLC Classification
11/24
06/25
BREAKWATER, NCT04607421 / 2020-001288-99: A Study of Encorafenib Plus Cetuximab With or Without Chemotherapy in People With Previously Untreated Metastatic Colorectal Cancer

Calendar Jan 2025 - Dec 2025: Approval for 1L BRAFV600E metastatic CRC (based on BREAKWATER trial)
Checkmark Data from the safety lead-in portion of BREAKWATER trial in BRAF V600E-mutant mCRC at ASCO-GI 2023
Jan 2023 - Jan 2023: Data from the safety lead-in portion of BREAKWATER trial in BRAF V600E-mutant mCRC at ASCO-GI 2023
Recruiting
3
815
Europe, Canada, Japan, US, RoW
Encorafenib, Braftovi, PF-07263896, LGX818, ONO-7702, Cetuximab, Erbitux, Oxaliplatin, Eloxatin, Irinotecan, Campostar, Leucovorin, Wellcovorin, Fusilev, Khapzory, 5-FU, Fluorouracil, Capecitabine, Xeloda, Bevacizumab, Zirabev
Pfizer, Ono Pharmaceutical Co. Ltd, Merck KGaA, Darmstadt, Germany, Eli Lilly and Company
Neoplasms
01/25
11/26
COPEC, NCT04922853: Comparison of the Pathological Effect Between 2 and 4 Cycles Neoadjuvant CAPOX for Low/Intermediate Risk II/III Rectal Cancer

Recruiting
3
554
RoW
Capox chemotherapy
West China Hospital, The Third People's Hospital of Chengdu, Chengdu Fifth People's Hospital, Peking Union Medical College, Beijing Cancer Hospital, Sun Yat-sen University, Second Affiliated Hospital, School of Medicine, Zhejiang University, Yunnan Cancer Hospital, The First Affiliated Hospital of Zhengzhou University, The Affiliated Hospital Of Guizhou Medical University, Sichuan Provincial People's Hospital, Nanchong Central Hospital, Dazhou Central Hospital, Leshan People's Hospital, GeneCast Biotechnology Co., Ltd.
Rectal Cancer, Neoadjuvant Chemotherapy
12/24
12/26
NCT05751850: HR070803 in Combination With Oxaliplatin, 5-FU/LV Versus AG for First-line Treatment of Advanced Pancreatic Cancer

Recruiting
3
778
RoW
HR070803; Oxaliplatin; 5Fluorouracil; Calcium folinate, nab-paclitaxel; gemcitabine
Jiangsu HengRui Medicine Co., Ltd.
First-line Treatment of Advanced Pancreatic Cancer
12/24
12/25
NCT04233151: QL1203 In Combination With Chemotherapy for Metastatic Colorectal Cancer to Determine Efficacy and Safety

Recruiting
3
590
RoW
QL1203, Placebo, mFOLFOX6 regimen
Qilu Pharmaceutical Co., Ltd.
Metastatic Colorectal Cancer
12/24
07/25
NCT04854668: A Study of Anlotinib Hydrochloride Capsule Combined With Chemotherapy as First-line Treatment in Subjects With RAS/BRAF Wild Metastatic Colorectal Cancer

Active, not recruiting
3
748
RoW
Anlotinib hydrochloride capsule, Bevacizumab, Oxaliplatin, Capecitabine
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Metastatic Colorectal Cancer
12/24
12/25
MATTERHORN, NCT04592913 / 2019-001555-40: Assessing Durvalumab and FLOT Chemotherapy in Resectable Gastric and Gastroesophageal Junction Cancer

Calendar Jan 2024 - Dec 2024: Acceptance of regulatory submission for neo-adjuvant/adjuvant gastric (based on MATTERHORN trial)
Calendar Jan 2024 - Dec 2024: Data from MATTERHORN trial for gastric and gastroesophageal Cancer
Hourglass Jul 2020 - Dec 2020 : From trial for MDS
Active, not recruiting
3
958
Europe, Canada, Japan, US, RoW
Durvalumab, FLOT chemotherapy
AstraZeneca
Gastrointestinal Neoplasms, Esophagogastric Junction
10/25
09/27
NCT04950322: A Trial of SHR1701 Plus Chemotherapy in Patients With Gastric or Gastroesophageal Cancer

Active, not recruiting
3
737
RoW
SHR-1701、CAPOX, Placebo、CAPOX
Suzhou Suncadia Biopharmaceuticals Co., Ltd.
Gastric or Gastroesophageal Junction Cancer
03/25
06/25
STARGLO, NCT04408638 / 2020-001021-31: A Phase III Study Evaluating Glofitamab in Combination With Gemcitabine + Oxaliplatin vs Rituximab in Combination With Gemcitabine + Oxaliplatin in Participants With Relapsed/Refractory Diffuse Large B-Cell Lymphoma

Calendar Jan 2023 - Dec 2024: Data readout from STARGLO trial in combination with gemcitabine and oxaliplatin for r/r DLBCL
Calendar Jan 2023 - Dec 2024: Data readout from STARGLO trial in combination with gemcitabine and oxaliplatin for r/r DLBCL
Feb 2023 - Dec 2023: Data readout from STARGLO trial in combination with gemcitabine and oxaliplatin for 2L+ DLBCL
Recruiting
3
270
Europe, US, RoW
Obinutuzumab, Glofitamab, Rituxumab, Tocilizumab, Gemcitabine, Oxaliplatin
Hoffmann-La Roche
Diffuse Large B-cell Lymphoma
04/25
04/25
SUNMO, NCT05171647: A Study Evaluating Efficacy and Safety of Mosunetuzumab in Combination With Polatuzumab Vedotin Compared to Rituximab in Combination With Gemcitabine Plus Oxaliplatin in Participants With Relapsed or Refractory Aggressive B-Cell Non-Hodgkin's Lymphoma

Calendar Jan 2023 - Dec 2024: Data from SUNMO trial in combination with polivy for 2L+ DLBCL
Recruiting
3
222
Canada, Japan, US, RoW
Mosunetuzumab, Polatuzumab vedotin, Tocilizumab, Rituximab, Gemcitabine, Oxaliplatin
Hoffmann-La Roche
Non-Hodgkin Lymphoma
05/25
11/27
CheckMate 8HW, NCT04008030 / 2018-000040-26: A Study of Nivolumab, Nivolumab Plus Ipilimumab, or Investigator's Choice Chemotherapy for the Treatment of Participants With Deficient Mismatch Repair (dMMR)/Microsatellite Instability High (MSI-H) Metastatic Colorectal Cancer (mCRC)

Calendar Jan 2024 - Dec 2024: Data readout from P3 CheckMate 8HW trial for 1L+ MSI High CRC
Jan 2023 - Dec 2023: Submission in Japan in combination with Yervoy for 1L colorectal cancer (based on CHECKMATE 8HW trial)
Jan 2023 - Dec 2023: Submission in Japan in combination with Opdivo for 1L colorectal cancer (based on CHECKMATE 8HW trial)
Recruiting
3
831
Europe, Canada, Japan, US, RoW
Ipilimumab, Oxaliplatin, Leucovorin, Fluorouracil, Irinotecan, Bevacizumab, Cetuximab, Nivolumab
Bristol-Myers Squibb, Ono Pharmaceutical Co. Ltd
Metastatic Colorectal Cancer
06/25
06/26
LOTIS 5, NCT04384484 / 2020-000241-14: Study to Evaluate Loncastuximab Tesirine With Rituximab Versus Immunochemotherapy in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma

Checkmark Safety run-in data from LOTIS-5 trial in combination with rituximab in r/r DLBCL at SOHO 2022
Sep 2022 - Sep 2022: Safety run-in data from LOTIS-5 trial in combination with rituximab in r/r DLBCL at SOHO 2022
Hourglass Sep 2021 - Dec 2021 : Submission for r/r DLBCL
Hourglass Nov 2021 - Dec 2021 : From LOTIS 5 trial in combination with rituximab for DLBCL
Recruiting
3
350
Europe, Canada, Japan, US, RoW
Loncastuximab Tesirine, Zynlonta, ADCT-402, Rituximab, Gemcitabine, Oxaliplatin
ADC Therapeutics S.A., ADC Therapeutics SA
Relapsed Diffuse Large B-Cell Lymphoma, Refractory Diffuse Large B-Cell Lymphoma
06/25
06/28
FORTITUDE-101, NCT05052801 / 2021-003461-35: Bemarituzumab or Placebo Plus Chemotherapy in Gastric Cancers With Fibroblast Growth Factor Receptor 2b (FGFR2b) Overexpression

Active, not recruiting
3
516
Europe, Canada, Japan, US, RoW
Bemarituzumab, mFOLFOX6, Placebo
Amgen, Zai Lab (China only)
Gastric Cancer, Gastroesophageal Junction Adenocarcinoma
08/25
08/25
MOUNTAINEER-03, NCT05253651 / 2021-002672-40: A Study of Tucatinib With Trastuzumab and mFOLFOX6 Versus Standard of Care Treatment in First-line HER2+ Metastatic Colorectal Cancer

Recruiting
3
400
Europe, Canada, Japan, US, RoW
tucatinib, TUKYSA, ONT-380, ARRY-380, trastuzumab, Herceptin, bevacizumab, Avastin, cetuximab, Erbitux, oxaliplatin, leucovorin, levoleucovorin, fluorouracil
Seagen Inc., Merck Sharp & Dohme LLC
Colorectal Neoplasms
08/25
04/28
NCT06093425: Combination of TST001, Nivolumab and Chemotherapy as First-line Therapy in Advanced or Metastatic GC/GEJ Adenocarcinoma

Not yet recruiting
3
950
NA
TST001, CapOx or mFOLFOX6 and NIVO or (Substudy) TST001, Oxaliplatin and capecitabine or 5-fluorouracil (5-FU), TST001 and Oxaliplatin and capecitabine or 5-fluorouracil (5-FU), folinic acid and oxaliplatin and Nivolumab, Placebo CapOx or mFOLFOX6 and NIVO or (Substudy) Placebo, Oxaliplatin and capecitabine or 5-fluorouracil (5-FU), Placebo and Oxaliplatin and capecitabine or 5-fluorouracil (5-FU), folinic acid and oxaliplatin
Suzhou Transcenta Therapeutics Co., Ltd.
Gastric Cancer, Gastroesophageal-junction Cancer, Advanced Cancer
10/25
01/26
LEAP-014, NCT04949256 / 2020-001911-26: Efficacy and Safety of Pembrolizumab (MK-3475) Plus Lenvatinib (E7080/MK-7902) Plus Chemotherapy in Participants With Metastatic Esophageal Carcinoma (MK-7902-014/E7080-G000-320/)

Hourglass Jan 2022 - Jan 2022 : Data from LEAP trial in combination with Keytruda for esophageal squamous cell carcinoma at ASCO-GI 2022
Recruiting
3
862
Europe, Canada, Japan, US, RoW
Pembrolizumab, MK-3475, KEYTRUDA®, Lenvatinib, MK-7902, E7080, LENVIMA®, Cisplatin, PLATINOL®, 5-FU, ADRUCIL®, Oxaliplatin, ELOXATIN®, Leucovorin, calcium folinate, folinic acid, WELLCOVORIN®, Levoleucovorin, calcium levofolinate, levofolinic acid, FUSILEV®, Paclitaxel, TAXOL®, ONXAL®
Merck Sharp & Dohme LLC, Eisai Inc.
Metastatic Esophageal Squamous Cell Carcinoma
12/25
12/25
NCT05244642: A Phase III Study to Evaluate the Efficacy and Safety of Penpulimab in the Relapsed and Refractory Classical Hodgkin's Lymphoma

Recruiting
3
60
RoW
Penpulimab, AK105, Investigator's choice of Chemotherapy
Akeso, Beijing Cancer Hospital
Hodgkin Disease Lymphoma
12/25
03/26
NCT05652894: A Study of HX008 Compared to Chemotherapy in the First-Line Treatment of Subjects With MSI-H/dMMR Metastatic Colorectal Cancer

Not yet recruiting
3
190
RoW
HX008, Investigator's Choice Chemotherapy
Taizhou Hanzhong biomedical co. LTD
Metastatic Colorectal Cancer
01/26
10/28
LEAP-015, NCT04662710 / 2020-001990-53: Efficacy and Safety of Lenvatinib (E7080/MK-7902) Plus Pembrolizumab (MK-3475) Plus Chemotherapy in Participants With Advanced/Metastatic Gastroesophageal Adenocarcinoma (MK-7902-015/E7080-G000-321/)

Active, not recruiting
3
890
Europe, Canada, Japan, US, RoW
Pembrolizumab, MK-3475, Keytruda®, Lenvatinib, MK-7902, E7080, Oxaliplatin, Capecitabine, Leucovorin (or Levoleucovorin), 5-FU
Merck Sharp & Dohme LLC, Eisai Inc.
Advanced/Metastatic Gastroesophageal Adenocarcinoma
02/26
02/26
TOURMALINE, NCT05771480: Durvalumab With Chemotherapy as First Line Treatment in Patients With Advanced Biliary Tract Cancers (aBTCs)

Recruiting
3
140
Europe, Japan, US, RoW
Durvalumab, Background Gemcitabine-based Chemotherapy Regimen, Gemcitabine monotherapy, Gemcitabine + cisplatin, Gemcitabine + oxaliplatin, Gemcitabine + carboplatin, Gemcitabine + cisplatin + S-1, Background Gemcitabine-based Chemotherapy Regimen., This regimen is not allowed for countries in the European Union., Gemcitabine + S-1, Gemcitabine + cisplatin + albumin-bound paclitaxel, Background gemcitabine-based chemotherapy Regimen
AstraZeneca
Biliary Tract Cancer
09/25
03/26
STAR-221, NCT05568095: A Clinical Trial of a New Combination Treatment, Domvanalimab and Zimberelimab, Plus Chemotherapy, for People With an Upper Gastrointestinal Tract Cancer That Cannot be Removed With Surgery That Has Spread to Other Parts of the Body

Active, not recruiting
3
1040
Europe, Canada, Japan, US, RoW
Domvanalimab, AB154, Zimberelimab, AB122, Capecitabine, Fluorouracil, Leucovorin, Oxaliplatin, Nivolumab
Arcus Biosciences, Inc., Gilead Sciences, Taiho Pharmaceutical Co., Ltd.
Advanced Upper Gastrointestinal Tract Adenocarcinoma
05/26
05/26
CAREME, NCT05699746: CAPEOX vs Observation in Colorectal Cancer Patients With Positive MRD

Not yet recruiting
3
38
RoW
Capecitabine tablets, Oxaliplatin
Zhejiang University, GeneCast Biotechnology Co., Ltd.
Colorectal Cancer
09/26
12/26
FORTITUDE-102, NCT05111626 / 2021-003477-61: Bemarituzumab Plus Chemotherapy and Nivolumab Versus Chemotherapy and Nivolumab for FGFR2b Overexpressed Untreated Advanced Gastric and Gastroesophageal Junction Cancer

Recruiting
3
528
Europe, Canada, Japan, US, RoW
Bemarituzumab, AMG 552, Nivolumab, Chemotherapy, Placebo
Amgen
Gastric Cancer, Gastroesophageal Junction Adenocarcinoma
09/26
09/26
MK-3475-C66, NCT05239741: Study of Pembrolizumab (MK-3475) Versus Chemotherapy in Chinese Participants With Stage IV Colorectal Cancer

Recruiting
3
100
RoW
Pembrolizumab, KEYTRUDA®, MK-3475, Oxaliplatin, Leucovorin, 5-fluorouracil, 5-FU, Irinotecan, Bevacizumab, Cetuximab
Merck Sharp & Dohme LLC
Colorectal Neoplasms
11/26
11/26
NCT05144854: A Study to Evaluate the Efficacy and Safety of ONO-4538 in Combination With Ipilimumab and Chemotherapy in Chemotherapy-naïve Participants With HER2-negative Unresectable Advanced or Recurrent Gastric Cancer (Including Esophagogastric Junction Cancer)

Active, not recruiting
3
626
Japan, RoW
ONO-4538, Nivolumab, Opdivo, Ipilimumab, BMS-734016, Yervoy, Oxaliplatin, Capecitabine, S-1, Tegafur-gimeracil-oteracil potassium
Ono Pharmaceutical Co. Ltd
Gastric Cancer
02/27
05/27
KEYNOTE 975, NCT04210115 / 2019-002006-51: Study of Pembrolizumab (MK-3475) Versus Placebo in Participants With Esophageal Carcinoma Who Are Receiving Chemotherapy and Radiation Therapy (MK-3475-975/KEYNOTE-975)

Calendar Jan 2026 - Dec 2026: Data from KEYNOTE-975 trial for esophageal cancer
Active, not recruiting
3
700
Europe, Canada, Japan, US, RoW
pembrolizumab, MK-3475, KEYTRUDA®, placebo, Normal saline solution, cisplatin, PLATINOL®, 5-FU, ADRUCIL®, radiotherapy, leucovorin, calcium folinate, folinic acid, levoleucovorin, FUSILEV®, calcium levofolinate, levofolinic acid, oxaliplatin, ELOXATIN®
Merck Sharp & Dohme LLC
Esophageal Squamous Cell Carcinoma (ESCC), Gastroesophageal Junction Carcinoma (GEJC), Esophageal Adenocarcinoma (EAC)
02/27
02/27
NCT05700448: Study of Sugemalimab (or Placebo) Plus PGemOx Regimen in Participants With Extranodal NK/T-Cell Lymphoma

Not yet recruiting
3
150
NA
Sugemalimab, Placebo, Pegaspargase, Gemcitabine, Oxaliplatin
CStone Pharmaceuticals
Extranodal NK/T-cell Lymphoma
11/27
11/28
NCT05314998: Adjuvant Trial in Patients With Resected PDAC Randomized to Allocation of Oxaliplatin- or Gemcitabine-based Chemotherapy by Standard Clinical Criteria or by a Transcriptomic Treatment Specific Stratification Signature

Not yet recruiting
3
394
Europe
Oxaliplatin, Irinotecan, Folinic acid, 5-fluorouracil, Gemcitabine, Capecitabine
John Neoptolemos, Molecular Health GmbH, Deutsches Krebsforschungszentrum (DKFZ), Nationales Centrum für Tumorerkrankungen, Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest, Institut für Medizinische Biometrie
Pancreatic Ductal Adenocarcinoma
01/31
09/31
ATTRACTION-4, NCT02746796: Study of ONO-4538 in Gastric Cancer

Checkmark From ATTRACTION-4 trial in combination with chemo in 2L gastric cancer at ESMO 2020
Sep 2020 - Sep 2020: From ATTRACTION-4 trial in combination with chemo in 2L gastric cancer at ESMO 2020
Completed
2/3
680
Japan, RoW
ONO-4538, Oxaliplatin, Tegafur- Gimeracil-Oteracil potassium, Capecitabine, Placebo
Ono Pharmaceutical Co. Ltd
Gastric Cancer
01/20
11/22
CheckMate 9X8, NCT03414983 / 2017-003662-27: An Investigational Immunotherapy Study of Nivolumab With Standard of Care Therapy vs Standard of Care Therapy for First-Line Treatment of Colorectal Cancer That Has Spread

Hourglass Apr 2021 - Sep 2021 : From CheckMate 9X8 trial in combination with Avastin for 1L CRC
Completed
2/3
196
Europe, Canada, Japan, US
Nivolumab, BMS-936558, Opdivo, Oxaliplatin, Leucovorin, Calcium Folinate, Fluorouracil, Bevacizumab, Avastin
Bristol-Myers Squibb, Ono Pharmaceutical Co. Ltd
Colorectal Cancer
02/21
12/22
2021-003313-18: A Research Study, where the participant and healthcare providers are aware of the treatment being given, to evaluate the most effective dose and the safety of medication MK-2140 when combined with standard treatments in patients with Diffuse Large B-Cell Lymphoma who failed prior therapies.

Ongoing
2/3
420
Europe
Zilovertamab Vedotin, Gemcitabine hydrochloride, Bendamustine Chydrochloride, Oxaliplatin, MK-2140, Solution for injection, Powder for solution for infusion, Concentrate for solution for infusion, Powder for concentrate for solution for infusion, Gemcitabine SUN, Bendamustin medac, Oxaliplatin AqVida, MabThera 100mg, MabThera 500 mg
Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc., MERCK SHARP & DOHME LLC. UNA SUSSIDIARIA DI MERCK & CO. INC., Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc., MERCK SHARP & DOHME LLC. UNA SUSSIDIARIA DI MERCK & CO. INC.
Treatment of participants with Relapsed or Refractory Diffuse Large B-Cell Lymphoma, Diffuse Large B Cell Lymphoma (a type of non-Hodgkin's lymphoma, in patients who failed prior therapies), Diseases [C] - Cancer [C04]
 
 
NCT04856787: A Clinical Studyf of SHR-1701 or Placebo in Combination With BP102 and XELOX in the First-line Treatment of mCRC

Recruiting
2/3
439
RoW
SHR-1701、 BP102 、XELOX, placebo、 BP102、 XELOX
Suzhou Suncadia Biopharmaceuticals Co., Ltd.
Metastatic Colorectal Cancer (mCRC)
11/22
11/24
MAHOGANY, NCT04082364: Combination Margetuximab, Retifanlimab, Tebotelimab, and Chemotherapy Phase 2/3 Trial in HER2+ Gastric/GEJ Cancer

Checkmark Interim data from cohort A part 1 of MAHOGANY trial in combination with retifanlimab for advanced HER2+ gastric cancer at ESMO 2021
Sep 2021 - Sep 2021: Interim data from cohort A part 1 of MAHOGANY trial in combination with retifanlimab for advanced HER2+ gastric cancer at ESMO 2021
Checkmark Safety and efficacy data from cohort A of MAHOGANY trial in combination with INCMGA00012 for gastroesophageal junction cancerat ESMO 2021
Sep 2021 - Sep 2021: Safety and efficacy data from cohort A of MAHOGANY trial in combination with INCMGA00012 for gastroesophageal junction cancerat ESMO 2021
Hourglass Sep 2020 - Mar 2021 : Completion of enrollment of module A of MAHOGANY trial
More
Active, not recruiting
2/3
82
Europe, US, RoW
margetuximab, MGAH22, Margenza®, Retifanlimab, MGA012, INCMGA00012, Tebotelimab, MGD013, Trastuzumab, Herceptin, Chemotherapy
MacroGenics, Zai Lab (Shanghai) Co., Ltd.
Gastric Cancer, Gastroesophageal Junction Cancer, HER2-positive Gastric Cancer
01/24
06/25
NCT05980481: A Study of RC48-ADC Combination Therapies as First-line Treatment in Advanced Metastatic Gastric Cancer

Recruiting
2/3
130
RoW
RC48-ADC, Disitamab Vedotin, Trastuzumab Injection, Trastuzumab, Toripalimab, JS001, Oxaliplatin injection, Oxaliplatin, Capecitabine, Capecitabine Tablets
RemeGen Co., Ltd.
Gastric Cancer
07/24
07/25
CAIRO6, NCT02758951 / 2016-001865-99: Perioperative Systemic Therapy for Isolated Resectable Colorectal Peritoneal Metastases

Recruiting
2/3
358
Europe
Perioperative systemic therapy, Perioperative CAPOX-bevacizumab, Perioperative FOLFOX-bevacizumab, Perioperative FOLFIRI-bevacizumab, CRS-HIPEC, experimental arm, CRS-HIPEC, control arm
Koen Rovers, Dutch Cancer Society, Comprehensive Cancer Centre The Netherlands, Hoffmann-La Roche
Colorectal Neoplasm, Colorectal Cancer, Colorectal Neoplasms Malignant, Colorectal Carcinoma, Colorectal Adenocarcinoma, Peritoneal Neoplasms, Peritoneal Carcinomatosis, Peritoneal Cancer, Peritoneal Metastases, Peritoneal Neoplasm Malignant Secondary Carcinomatosis, Peritoneal Neoplasm Malignant Secondary
08/24
08/26
NIVEAU, NCT03366272 / 2016-002272-27: Nivolumab With Gemcitabine, Oxaliplatin + Rituximab in r/r Elderly Lymphoma Patients

Active, not recruiting
2/3
348
Europe, RoW
Nivolumab, Rituximab, Gemcitabine, Oxaliplatin
Universität des Saarlandes, Bristol-Myers Squibb, Lymphoma Study Association, University of Leipzig
Lymphoma, Non-Hodgkin
11/24
11/24
ASTRUM-015, NCT04547166: A Clinical Study to Evaluate Efficacy and Safety of Serplulimab（HLX10） Combined With Bevacizumab（HLX04) and Chemotherapy (XELOX) in Patients With Metastatic Colorectal Cancer (mCRC)

Recruiting
2/3
568
Japan, RoW
HLX10, serplulimab, HLX04、, Bevacizumab
Shanghai Henlius Biotech
Metastatic Colorectal Cancer
09/25
12/26
FROST, NCT05179889: Adjuvant mFOLFIRINOX for High-risk Stage III Colon Cancer

Enrolling by invitation
2/3
308
RoW
mFOLFIRINOX, mFOLFOX 6
Chungnam National University Hospital, Boryung Pharmaceutical Co., Ltd
Colon Cancer Stage III
03/25
03/28
NCT05945901: A Phase II/III Study of HR070803 in Combination With Oxaliplatin, 5-fluorouracil, Calcium Folinate and Bevacizumab Versus FOLFOX in Combination With Bevacizumab for First-line Treatment of Advanced Colorectal Cancer

Recruiting
2/3
606
RoW
HR070803 plus oxaliplatin, 5-FU/LV, bevacizumab, HR070803 simulator plus oxaliplatin, 5-FU/LV, bevacizumab
Jiangsu HengRui Medicine Co., Ltd.
Colorectal Cancer
12/25
12/26
waveLINE-003, NCT05139017 / 2021-003313-18: A Study of Zilovertamab Vedotin (MK-2140) in Combination With Standard of Care in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (rrDLBCL) (MK-2140-003)

Recruiting
2/3
260
Europe, Canada, US, RoW
Zilovertamab vedotin, MK-2140, VLS-101, Rituximab, Rituxan®/mabthera, Truxima® (rituximab-abbs), RUXIENCE®), Gemcitabine, Gemzar®, Oxaliplatin, Eloxatin®, Bendamustine, Bendeka®, Treanda®, Belrapzo®
Merck Sharp & Dohme LLC, Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc., MERCK SHARP & DOHME LLC. UNA SUSSIDIARIA DI MERCK & CO. INC.
DLBCL, Diffuse Large B-Cell Lymphoma
06/27
06/27
STOP-PC, NCT06079346: A Study of OT-101 With mFOLFIRINOX in Patients With Advanced and Unresectable or Metastatic Pancreatic Cancer

Recruiting
2/3
455
US
OT-101, mFOLFIRINOX
Oncotelic Inc.
Pancreatic Ductal Adenocarcinoma
06/26
06/27
GRANITE, NCT05141721: A Study of a Patient-Specific Neoantigen Vaccine in Combination With Immune Checkpoint Blockade for Patients With Metastatic Colorectal Cancer

Active, not recruiting
2/3
700
US
GRT-C901, GRT-R902, Atezolizumab, Tecentriq, Ipilimumab, Yervoy, Fluoropyrimidine plus leucovorin, Xeloda, Bevacizumab, Avastin
Gritstone bio, Inc.
Colorectal Neoplasms
03/27
03/27
NCT05149807: Clinical Study of SHR-1701 Plus Chemotherapy as Perioperative Treatment in Subjects With Gastric Cancer

Enrolling by invitation
2/3
896
RoW
SHR-1701 injection, Placebo
Suzhou Suncadia Biopharmaceuticals Co., Ltd.
Perioperative Treatment in Subjects With Locally Advanced Resectable Gastric Cancer or Gastroesophageal Junction Cancer
07/27
12/27
 

Download Options